PDF
ZENODO
Published
2026-02-14
Section
Articles
How to Cite
How to Cite
EARLY DIAGNOSIS OF COGNITIVE IMPAIRMENT IN ALZHEIMER’S DISEASE
Choriyev Shohjahon
Student, Faculty of Medicine, Termiz University of Economics and Service
Alimova Zebiniso
Faculty of Medicine, Termiz University of Economics and Service
Keywords: Alzheimer’s disease; mild cognitive impairment (MCI); early diagnosis; cognitive screening; functional assessment; biomarkers; AT(N); MRI/CT; PET; blood-based biomarkers.
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia and is characterized by progressive cognitive decline. Early identification of AD is essential to stage the disease, assess risk, and prepare an advance care plan for the patient and family. This review discusses clinical and biological notions of “early” AD, and summarizes a stepwise diagnostic pathway: clinical evaluation, brief cognitive screening, functional assessment, exclusion of reversible causes, structural neuroimaging, and targeted use of biomarkers (CSF, PET, and blood-based markers). The recent expansion of blood-based biomarkers can make early diagnosis more accessible, but these tests must not be used as stand‑alone screening or diagnostic tools; results require interpretation within the clinical context.
References
1. Shodmonov X.Q., Eshmurodov X.Sh., Tursunova O.T. Nervous and Mental Disorders (Asab va ruhiy kasalliklar): Study guide for medical colleges. Tashkent: Bilim Publishing House, 2004. 200 p.
2. Majidov N.M. General Neurology (Umumiy nevrologiya). Tashkent, 1995.
3. Shomansurov Sh.Sh. Nervous and Mental Disorders (Asab va ruhiy kasalliklar). Tashkent, 1995.
4. Aslanov A.M. Nervous Diseases (Asab kasalliklari). Tashkent, 1998.
5. Murtalibov Sh.A. Handbook of Psychiatry (Psixiatriyadan ma’lumotnoma). Tashkent, 1993.
6. Shomansurov Sh.Sh. Pediatric Nervous Diseases (Bolalar asab kasalliklari). Tashkent, 1995.
7. Rustamova M., Xo‘jamberdiev M. Geriatrics (Geriatriya): Textbook. Tashkent, 2012.
8. Razikova I.S., Alikulova D.Ya. Nursing in Gerontology (Gerontologiyada hamshiralik ishi). Textbook (Uzbek). Tashkent, 2018.
9. Nasriddinova N.N. Gerontology and General Geriatrics (Gerontologiya va umumiy geriatriya): Study guide. Tashkent: Barkamol Fayz Media, 2018. 164 p.
10. Alzheimer’s Association. Criteria for Diagnosis and Staging of Alzheimer’s Disease. 2024.
11. Jack C.R. Jr., et al. Revised criteria for diagnosis and staging of Alzheimer’s disease. Alzheimer’s & Dementia. 2024.
12. U.S. Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer’s disease (Lumipulse G pTau217/β Amyloid 1 42 Plasma Ratio). May 16, 2025.
13. Palmqvist S., et al. Alzheimer’s Association Clinical Practice Guideline on the use of blood based biomarkers in the diagnostic workup of Alzheimer’s disease within specialty care. 2025.
14. Ashton N.J., et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurology. 2024.
15. Jack C.R. Jr., et al. NIA AA Research Framework: Toward a biological definition of Alzheimer’s disease (AT(N)). 2018.
16. U.S. FDA. 510(k) Review: Lumipulse G pTau217/β Amyloid 1 42 Plasma Ratio (K242706). 2025.
17. Ibodullayev Z.R. Nervous Diseases (Asab kasalliklari). Textbook (2nd ed.). Tashkent, 2014. 1000 p.
